Skip to main
ONC
ONC logo

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines demonstrated strong financial performance in 2024, ending the year with US$2.6 billion in cash and reporting Brukinsa sales of US$2.6 billion, reflecting a remarkable 105% year-over-year increase. In addition, Tevimbra sales grew by 16% year-over-year to US$621 million, surpassing competitor Innovent’s Tyvyt sales, showcasing BeOne's competitive edge within the oncology therapeutics market. Furthermore, analysts have increased their revenue forecasts for 2025 through 2027 by 9.6% to 12.5%, driven by the robust sales momentum of Brukinsa, which has overtaken its rival Calquence in both revenue and market share.

Bears say

BeOne Medicines is currently facing significant financial challenges, highlighted by a net loss of $645 million in the most recent reporting period, despite a narrowing loss year-over-year. The company's revenue outlook appears bleak, with a revised peak sales estimate for its key drug, Tevimbra, reduced from $2 billion to $1.5 billion by 2035 and a substantial cut to the ociperlimab peak sales estimate from $342 million to $172 million. Additionally, the potential for further downside is exacerbated by concerns regarding the efficacy of ongoing clinical trials, which presents binary risks if results do not show significant benefits.

BeiGene Ltd (ONC) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 7 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $342.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $342.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.